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Summary: Three different allelic variants of apolipoprotein E determine, in concert with other gene products, the
levels of plasma lipoproteins. Recently, cleavage products of the complement C3 molecule have also been impli-
cated in determining plasma triacylglycerol concentrations.
This study presents data of an ongoing study to dissect the role of the apolipoprotein E gene locus in the response
to low fat/low cholesterol diet combined with gemfibrozil treatment. In addition, for the first time, the significance
of C3 allelic variants to such hypolipidaemic therapy response was analysed. To this end data from 81 obese
hyperlipoproteinaemic patients (Fredrickson type II/A and B and type IV and V) confirmed the usefulness of the
combined gemfibrozil/diet treatment and unveiled apolipoprotein E allele group specific therapy responses. The
mean changes of lipid properties due to combined treatment was 15% for total cholesterol, 48% for triacylglycerols
and 28% for atherogenic index. Division into hyperlipidaemia types according to Fredrickson and subgrouping into
E2, E3 and E4 groups (apolipoprotein E2/2 and 2/3, apolipoprotein E3/3 and apolipoprotein E4/2 and 4/3 phenotype
groups respectively) exposed pronounced differences from these mean changes, suggesting substantial influence of
apolipoprotein E variants on this therapy. We observed triacylglycerol reductions of from 17% in type IIA-apolipo-
protein E3 group patients up to 78% in the type IV and V-apolipoprotein E2 group. Thus it might be concluded the
apolipoprotein E genotyping aides therapy success prediction. Although, low sample numbers in some subgroups
obscures significance in this pilot study, significant therapy success emerges for the E3 and E4 group in type IV
and V hyperlipidaemia and type IIB-apolipoprotein E3 homozygous patients can be predicted to respond better
than apolipoprotein E2 carriers.
Finally, we present evidence that positive changes of lipid properties are also determined by the "fast" complement
C3 allel (C3-F). Patients with complement factor C3-FS pattern respond better to treatment than patients with C3-
SS configuration, In summary these data endorse the genotyping of apolipoprotein E alleles to predict maximal
success of "fibrate" treatment. In addition they argue strongly for further assessment of the involvement of comple-
ment C3 allelic variations in lipid homeostasis.
Introduction
Apolipoprotein E, a MT = 34 000 protein, is one of the VLDL (very low density lipoprotein) and the remnants
key molecules involved in lipid metabolism. Apolipo- thereof (DDL), thereby controlling plasma triacylglycerol
protein E controls the catabolism of chylomicrons, levels by its capacity to bind to both the apolipoprotein
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E LDL receptor related protem/a2-macroglobulin-recep-
tor and the LDL receptor (1, 2). The amino-terminal do-
main of apolipoprotein E, around arginine 158, contains
the region that binds to the cysteine rich repeats on the
LDL and LDL receptor related protein/a2-macrpglobu-
lin-receptor (2) which bears homologous repeats. The
human apolipoprotein E gene spans 3.7 Χ 103 bases in-
cluding four exons (3, 4) and is located on chromosome
19 (4) in a gene family that is also close to the locus of
the complement factor C3 gene (5). Apolipoprotein E
polymorphic with three common isoforms, ε2 (112cys,
ISScys), ε3 (112cys, 158arg, the most common) and ε4
(112arg, 158arg), which are determined by separate
alleles at the apolipoprotein Ε locus. There are thus
six widespread apolipoprotein E phenotypes in the
population: homozygous E2/2, E3/3, E4/4 and hetero-
zygous E3/2, E4/2 and E4/3 (6). The apolipoprotein
E4 with two arginines in the binding region has higher
affinity and apolipoprotein E2 with two cysteins has
a lower affinity for LDL receptor than apolipoprot-
ein E3.
As the lipoprotein levels in blood are governed by their
affinity for receptors, low density lipoprotein (LDL)
cholesterol concentrations vary with apolipoprotein E.
Lipoprotein levels are highest in people bearing the al-
lele ε4 (but apolipoprotein E serum levels are lower (7)),
intermediate in those with ε3 and lowest in those with
ε2 (8, 9). This occurs because in persons carrying the
allele ε4, the high affinity of apolipoprotein E4 carrying
particles leads to an oversupply of liver cells with cho-
lesterol. As a consequence, LDL receptors are made in-
active which leads to less efficient removal of IDL and
enhanced conversion to LDL. Consequently accumula-
tion and prolonged circulation of LDL in the blood-
stream is observed (10). The genotype homozygous for
allele ε2 is associated with delayed chylomicron clear-
ance but raised apolipoprotein E levels (7) after high-fat
load. The ε2 allele is also associated with delayed clear-
ance of the IDL/VLDL remnant fraction and LDL recep-
tor levels are not down regulated as no oversupply of
cells with IDL exists. In the treatment with anti-hyper-
lipidaemic drugs a more precise prediction of efficiency
is desirable and might be possible by grouping patients
according to apolipoprotein E genotypes (11-14). For
the frequently used anti-hyperlipidaemic drugs (hydro-
xymethylglutaryl-CoA reductase inhibitors, type simva-,
lova-, pravastatin and chlorophenoxy methylpropionate
derivatives like clo-, feno-, etofibrate) predictable effects
on type II/B and IV forms of hyperlipidaemia are highly
desirable but not readily available (15, 16). It would be
usefiil to predict the individual reaction to various
classes of lipid lowering drugs thereby facilitating their
selection. Recent findings suggest that the human com-
plement factors C3 and C4 (C3, C4) are markers of a
genetic predisposition to myocardial infarction. C3 is lo-
cated in the vicinity of the apolipoprotein E gene locus
on chromosome 19 and C4 in the vicinity of the 21-
hydroxylase gene locus on chromosome 6. C3 levels
measured in sera from subjects without previous ischae-
mic events are independently associated with the risk of
myocardial infarction (17). A certain C4 allotype
(C4B*QO) had higher prevalence in men with myocar-
dial infarction (18). C3 was reported to be involved in
the regulation of the adipsin/acylation stimulating pro-
tein system which seems to play a pivotal role in
regulation of triacylglycerol removal from plasma (19).
It was found that acylation stimulating protein is iden-
tical with the cleavage product of complement factor
C3, named C3a-desArg, and stimulates triacylglycerol
synthesis in human adipocytes. We therefore tested
whether alleles of C3 or C4 are involved in plasma
lipid regulation and thus serve as risk factors for myo-
cardial infarction by analysing the lipid properties
changes linked to the occurrence of the C4B*QO allele
and the "fast" and "slow" alleles of complement C3
in our study group.
Methods
Patients
The study group consisted of 81 unrelated obese (body weight 30%
above ideal) outpatients, 27 females and 54 males with hyperlipi-
daemia (Fredrickson phenotype II/A = 13, II/B = 33, IV = 15,
V = 20), who were attending the lipid clinic of St. Emeric Hospi-
tal, Budapest. The principal criteria for entry was a cholesterol
concentration above 7.8 mmol/1 and/or triacylglycerol above 5.0
mmol/1. In all cases, analyses were performed before and after in-
terventions. The patients had been requested to consume a choles-
terol-lowering diet (less than 30% of daily energy as fat and daily
cholesterol intake < 200 mg, (19)) and were treated with gemfi-
brozil (Gevilon®, G decke Inc.) 900 mg at bedtime. They were
advised to adhere to this diet during the experimental period (6
months). Dietary advice was provided by a co-ordinated group of
registered dietitians throughout the study. None of the study group
had heart failure, renal, liver, or thyroid disease, or diabetes melli-
tus. Height and weight were obtained with a balance beam scale,
and body mass index (BMI), a measure of body fat, was obtained
by dividing body weight in kilograms by height in meters squared.
All patients volunteered for the study, which had been approved
by the Ethical Committee of the hospital.
Measurement of lipids, lipoproteins,
and apolipoproteins
Subjects were evaluated in the morning after a 12-hour fast
for the following measures: the concentrations of serum total cho-
lesterol and triacylglycerol were assayed enzymatically with a Hi-
tachi 717 automated analyzer according to the Manual of laboratory
Operations of the Lipid Research Clinics Program (20, 21).
High density lipoprotein (HDL) was isolated in the supernatant
after precipitation of apolipoprotein B-contairiing lipoproteins with
heparin and manganese chloride (22). Immunonephelometric assay
(Orion Inc./Turox Inc.) was used to measure the apolipoproteins
ΑΙ, ΑΠ and Β. Apolipoprotein E isoforms were characterised by
means of polymerase chain reaction (PCR) and restricion fragment
length polymorphism (RFLP) (23). Internal quality control was
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evaluated throughout the study with the use of on the one hand
7a#-DNA polymerase and template DNA-free samples, and on the
other, intra- and inter-observer crossover investigation. C3 and C4
(the third and fourth complement of the human complement sys-
tem) phenotypes were determined by high voltage electrophoresis
using the method of Teisberg (24, 18).
Monitoring for adverse events
At each visit, the pulse rate, sitting blood pressure and body weight
were recorded, and patients were questioned about »adverse events.
Routine biochemical and haematological analyses (including liver
and muscle functions) were performed by the central laboratory at
the run-in and at the end-period.
Statistical analyses
Statistical analyses were carried out with the BMDP statistical soft-
ware package (University of California, Los Angeles, CA, 1985).
Analysis of variance (ANOVA) was used for comparison of means.
For pairwise comparison of means Wilcoxon rank sum test was
applied, multiple stepwise regression analysis was done to dif-
ferentiate the influences affecting serum lipid levels (p < 0.05 was
considered statistically significant).
Results
Clinical characteristics and lipid- and apolipoprotein
properties of the study subjects before treatment (Base-
line) and after therapy (Intervention) are depicted in ta-
ble 1. The pre-treatment levels of total plasma choles-
terol, non-HDL cholesterol and apolipoprotein A-I were
significantly higher in females (not shown). The mean
changes of lipid properties in men and women due to
combined treatment was 15% for total cholesterol, 48%
for triacylglycerol and 28% for atherogenic index. Divi-
sion into hyperlipidaemia types according to Fred-
rickson and subgrouping into E2, E3 and E4 groups
(apolipoprotein E2/2 and 2/3, apolipoprotein E3/3 and
apolipoprotein E4/2 and 4/3 phenotype groups) exposed
pronounced differences from this mean changes, sug-
gesting substantial influence of apolipoprotein E vari-
ants on therapy efficacy. In table 2, triacylglycerol re-
ductions of from 17% in type IIA-apolipoprotein E3
group patients up to 78% in the type IV and V-apolipo-
Tab. 1 Clinical characteristics, lipid and apolipoprotein properties of the study subjects.
Variables (Units) Men (n = 54) Women (n = 27)
Limits Limits
mean ± SD (max, min) mean ± SD (max, min)
p values*
Independent variables
Age (a)
BMI (kg/m2 height)
A. Baseline
B. Intervention
49.0 ± 8.2
29.4 ± 4.9
28.2 ± 5.5
(66.9,34.0)
(45.4, 27.2)
51.2 ± 11.4
26.4 ± 4.3
(72.0, 26.0)
(44.3,20.1)
0.22
0.008
Dependent variables
total-cholesterol (mmol/1)
A. Baseline
B. Intervention
Triacylglycerol (mmol/1)
A. Baseline
B. Intervention
HDL cholesterol (mmol/1)
A. Baseline
B. Intervention
Non-HDL cholesterol (mmol/1)
A. Baseline
B. intervention
Atherogenic Index
A. Baseline
B. Intervention
Apolipoproteins (g/1)
-A-I
-A-II
-B
-B/A-I
7.5
6.7
6.4
4.1
0.8
1.1
6.6
5.6
9.8
7.3
1.5
0.3
1.1
0.8
±2.5
± 1.7
±5.7
±4.4
±0.3
±0.4
±2.6
±ί.7
±5.1
±2.6
±0.5
±0.2
±0.5
±0.4
(19.3,
(15.0,
(31.9,
(25.3,
(1.9,
(2.6,
(18.7,
(13.6,
(39.0,
(13.0,
(3.0,
(1.1,(2.3,
(1.9,
4.5)
4.3)
1.2)
1.0)
0.4)
0.4)
3.7)
3.6)
3.1)
3.1)
0.6)
0.1)
0.4
0.3)
8.4 ±
6.8 ±
7.7 ±
3.2 ±
0.9 ±
1.1 ±
7.4 ±
5.6 ±
9.7 ±
6.8 ±
1.7 ±
0.3 ±
1.0 ±
0.7 ±
2.8
1.2
8.6
3.7
0.2
0.3
2.0
1.4
3.6
3.4
0.4
0.1
0.5
0.4
(20.3,
(8.9,
(31.3,
(19.9,
(1.5,
(2.2,
(14.6,
(8.2,
(18.7,
(18.7,
(2.5,
(0.4,
(1.9,
(1.7,
5.2)
4.5)
1.3)
1.0)
0.5)
0.6)
4.9)
3.1)
4.9)
2.4)
1.0)
0.2)
0.4)
0.3)
0.49
0.59
0.06
0.14
0.22
0.02
0.84
0.83
0.26
0.02
0.11
0.40
0.22
Non-HDL cholesterol (VLDL cholesterol + LDL cholesterol), BMI (Body Mass Index),
* p values (Mann-Whitney u test), p < 0.05 significant.
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protein E2 group can be observed. Similar trends were
obvious with cholesterol and atherogenic index. They
are currently under investigation in the extended sample
pool and a complete table will provide a useful therapy
decision tool when Fredrickson Type of hyperlipidaemia
and apolipoprotein E genotype of a patient is known.
The apolipoproteins showed no statistically significant
distribution differences among apolipoprotein E geno-
types. Individual lipid and clinical data analysis for each
apolipoprotein E group and Fredrickson type of this pi-
lot study cohort are not shown but are available upon re-
quest.
In figure 1 the significant changes of properties occur-
ring in Fredrickson types along the different apolipo-
protein E genotype permutations are detailed. The num-
bers of patients (n) for each group are given. Values of
changes ((A-B)/A%, A: Baseline values, B: Post-inter-
vention values) that reached statistical significance (Wil-
coxon rank sum test, p < 0.05 significant) are lettered
S. in type IV and V the triacylglycerol values were sig-
nificantly lowered, while in IIB, with the same number
of patients, no significant changes were seen in the E2
group. Thus it seems conceivable that the apolipoprotein
E allelic variation will govern the therapy response in
the respective Fredrickson type hyperlipidaemias. The
apolipoprotein E alleles pooled frequencies were accord-
Tab. 2 Changes in triacylglycerol (mmol/1) during therapy be-
tween different Fredrickson phenotypes within apolipoprotein E
genotype groups.
Variables
II/A
II/B
IV + V
E2/E2, E2/E3
E2-Group
(n = 16)
25.0
20.0
77.86
E3/E3
E3-Group
(n = 45)
16.66
45.23
60.58
E4/E3, E4/E2
E4-Group
(n = 20)
20.0
52.38
76.66
E2
E3
E4
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Fig. l Pattern of significance of lipid properties changes along
apolipoprotein E allele groups and Fredrickson type hyperlipidae-
mias (n = number of patients in group). Baseline and post-inter-
vention values have been analysed by Wilcoxon rank sum test for
significance of difference. Cells were lettered with S when signifi-
cant changes were reached. Numbers of observations are given to
indicate where low sample size may obscure significance.
C4B*QO C3-SS C3-FS
A l l e l e s
Fig. 2 Reduction of lipid properties observed in the different
complement genotype groups. Bars marked with star show signifi-
cant changes, (left bar of triade = cholesterol, middle = triacyl-
glycerols, right = atherogenic index).
ing to the Hardy-Weinberg equilibrium, ε2 = 0.20,
ε3 = 0.67 and ε4 = 0.13 thus showing independence. In
summary figure 1 gives an overview of the relevant
properties cholesterol, triacylglycerols and atherogenic
index across the allele groups and Fredrickson types.
Responsiveness to therapy within identical apolipoprot-
ein Ε genotypes and significant beneficial therapeutic
trends could be seen in most properties with decreasing
order of allele influence: ε3 > ε4 > ε2. These positive
changes could be seen in spite of decreasing BMI values
during therapy.
The frequencies of the two most interesting C3 and C4
alleles (18), the first lying in the vicinity of the apolipo-
protein E gene locus on chromosome 19 and the latter
in the vicinity of the steroid 21-hydroxylase gene locus
on chromosome 6 ware also determined and related to
lipid properties. In the study group the frequencies of
C3-S and C3-F were 0.84 and 0.16, respectively, iden-
tical to those found in the healthy population. In figure
2, cholesterol, triacylglycerol and atherogenic index
changes are given in the various allele groups. Signifi-
cant decrease in atherogenic index could be seen only
in heterozygotes carrying C3-FS. The mean atherogenic
index during dietary measures for homozygous (C3-SS)
individuals decreased from 9.40 to 7.01 and for hetero-
zygotes (C3-FS) from 11.08 to 5.33 (p < 0.01). Changes
seen in carriers of the C4B*QO were not significant.
Discussion
Our results have shown that in obese hyperlipidaemic
Hungarian Caucasians the influence of apolipoprotein E
genotypes on baseline and post intervention lipid prop-
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erties differed from that found in previous studies car-
ried out in various populations with different ethnic and
socio-economic backgrounds (25-28). In our survey the
relative frequency of the 82 allele was as much as 3
times higher than in previous studies dealing with nor-
molipidaemic subjects from different ethnic groups
(0.20 vs. 0.06) (29), whereas no difference in the relative
frequency of the ε4 allele between two study groups was
seen (0.13 vs. 0.13). The ε4 allele carriers were prone to
higher initial lipid properties and BMI values and they
also showed a pronounced positive therapy response. By
using ANOVA we could not detect significant differ-
ences in therapy response between various apolipoprot-
ein E genotypes in Fredrickson type II/A and IV 4- V.
In type IIA this might be explained by the relatively
small number in the subgroup and was predicted to
reach significant levels at total sample sizes above 300
by cluster analysis technique. In accordance with previ-
ous findings we could also detect the coincidence of 82
allele and higher cholesterol levels mainly in type IV
and V hyperlipidaemia (compare 1. c. (29)).
Allelic variation in apolipoprotein E has the greatest im-
pact on plasma levels of cholesterol, triacylglycerol, and
apolipoprotein B, C-II, and E (11, 12, 31-33). It has
been suggested that ε4 could tip a compromised lipolytic
system in obese (relative insulin insufficiency, decreased
! lipoprotein lipase activity, prolonged postprandial lipae^
! mia) into frank phenotypic expression of dyslipidaemia.
The triacylglycerol substrate bound to apolipoprotein Ε
1
 has a greater capacity to activate lipoprotein lipase and
the extent of this capacity may be related to the amount
of apolipoprotein Ε bound to triacylglycerol (34—36,
38). The triacylglycerol-rich particles in individuals with
84 are relatively poor in apolipoprotein E, as are the
VLDL from hyperlipoproteinaemia type IV subjects
(37). This metabolic alteration could unveil insufficient
lipoprotein lipase activation and/or the ineffective clear-
ance of lipid particles due to apolipoprotein E. Such
mechanisms might be operative in the type IV + V-E2
group leading to unconvincing response to therapy.
As a first consequence typing of ε alleles in obese Fred-
rickson type II/B has been statistically established to
successful predict treatment when 83 is detected. For
these patients, 32 out of 81 in our group, a convincing
correlation of the therapy success with the 83 genotype
(22 of 32) justifies putting such patients on combined
treatment.
Plasma C3 levels are associated with the risk of myocar-
dial infarction. The local activity of the complement sys-
tem may affect the response of the plasma lipid regula-
tory systems. The two common phenotypes of the apoli-
poprotein E neighboring C3 gene (C3-SS and C3-FS)
on chromosome 19 have different functional activity
(30). On the other hand, a cleavage product of human
complement C3 generated during complement activation
— or perhaps due to plasma lipid feedback mechanisms
— regulates plasma triacylglycerol removal. Thus, our
finding that the functionally more active C3-FS has a
better influence on diet may have not only a predictive
role, but also suggests that the fast complement C3 allele
product is more advantageous in adipsin/acylation stim-
ulating protein mediated plasma triacylglycerol regula-
tion. Our findings also motivate the elucidation of this
allele's participation in the adipsin/acylation stimulating
protein system.
In conclusion our results support the contention that
apolipoprotein E polymorphism modulates the therapy
response to combined dietary and gemfibrozil therapy.
Thus genotyping would, in the long run, be a useful
tool in selecting an effective antihyperlipidaemic ther-
apy.
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